Testosterone Replacement Therapy: Dosing, Forms & Monitoring

TL;DR

• Testosterone replacement therapy (TRT) is indicated for men with confirmed low serum testosterone (<300 ng/dL on two morning samples) plus clinical symptoms of hypogonadism.
• Multiple delivery forms exist — intramuscular injections, topical gels, transdermal patches, subcutaneous pellets, and nasal gel — each with distinct dosing schedules, pharmacokinetics, and adherence profiles.
• Testosterone replacement therapy dosing must be individualized; the goal is mid-normal range (450–600 ng/dL), not supraphysiological levels.
• The TRAVERSE trial (2023) demonstrated that TRT does not increase major adverse cardiovascular events in men aged 45–80 with cardiovascular risk factors.
• Monitoring hematocrit, PSA, lipids, and testosterone levels is mandatory — typically at 3, 6, and 12 months, then annually.

---

What Is Testosterone Replacement Therapy?

Testosterone replacement therapy dosing refers to the exogenous administration of testosterone to restore physiological serum concentrations in men diagnosed with hypogonadism — a condition defined by the Endocrine Society as a serum total testosterone level below 300 ng/dL (10.4 nmol/L) measured on at least two early-morning samples, combined with signs and symptoms such as decreased libido, erectile dysfunction, fatigue, reduced lean mass, or depressed mood.

Hypogonadism may be classified as:

• Primary (hypergonadotropic): Testicular failure with elevated LH/FSH — causes include Klinefelter syndrome, orchitis, chemotherapy, or trauma.
• Secondary (hypogonadotropic): Hypothalamic-pituitary dysfunction with low or inappropriately normal LH/FSH — causes include pituitary tumors, obesity, opioid use, or idiopathic.
• Late-onset (age-related): A functional decline in testosterone associated with aging and comorbidities, sometimes called "andropause." The Endocrine Society recommends against routine treatment of age-related decline in the absence of clear symptoms and confirmed biochemical deficiency.

Epidemiology. Population-based data from the European Male Ageing Study and the Baltimore Longitudinal Study of Aging suggest that biochemical hypogonadism (total testosterone <300 ng/dL) affects approximately 2–4% of men aged 40–49 and 10–20% of men over 60, though prevalence varies significantly by the threshold used and population studied.

---

Diagnosis Before Dosing: Who Qualifies for TRT?

Before initiating any testosterone replacement therapy dosing regimen, both the American Urological Association (AUA) and the Endocrine Society require:

1. Two morning serum total testosterone levels <300 ng/dL (drawn before 10:00 AM, fasting preferred)
2. Presence of clinical signs/symptoms of testosterone deficiency
3. Exclusion of reversible causes — obesity, opioid use, uncontrolled diabetes, hyperprolactinemia, obstructive sleep apnea
4. Exclusion of contraindications (see Contraindications section)

Free testosterone or bioavailable testosterone measurement is recommended when total testosterone is borderline (200–400 ng/dL) or when sex hormone-binding globulin (SHBG) abnormalities are suspected (e.g., obesity, aging, hepatic disease, thyroid disorders).

Key point: Initiating TRT without confirmed biochemical deficiency exposes patients to risks without expected benefit and is inconsistent with guideline recommendations.

---

TRT Delivery Methods: Head-to-Head Comparison

Several FDA-approved formulations are available for testosterone replacement therapy dosing. Each differs in pharmacokinetics, convenience, cost, and risk profile.

Clinical pearl: For patients concerned about fertility preservation, standard TRT suppresses the hypothalamic-pituitary-gonadal (HPG) axis and may cause azoospermia. Nasal testosterone (Natesto) and off-label alternatives such as clomiphene citrate or enclomiphene (selective estrogen receptor modulators that stimulate endogenous production) should be discussed with reproductive-age men.

---

Testosterone Replacement Therapy Dosing: Practical Guide

The Endocrine Society guideline (2018) recommends titrating testosterone replacement therapy dosing to achieve a mid-normal serum testosterone level of 450–600 ng/dL, avoiding supraphysiological concentrations. Below is a detailed dosing and titration guide by formulation.

Intramuscular Injections

Testosterone cypionate/enanthate:

• Starting dose: 100 mg IM every 7 days, or 200 mg IM every 14 days
• Titration: Check trough testosterone (drawn the morning before the next injection) at 8–12 weeks. Adjust dose in 25–50 mg increments.
• Target trough: 400–600 ng/dL
• Peak management: If patients report mood swings, acne, or erythrocytosis, consider splitting to more frequent, smaller doses (e.g., 50–75 mg every 3.5 days subcutaneously or intramuscularly) to flatten the pharmacokinetic curve.

Testosterone undecanoate (Aveed):

• Dose: 750 mg IM — first dose, second dose at 4 weeks, then every 10 weeks (±1 week)
• Monitoring: Serum testosterone at trough (just before next injection) after the third dose
• Special requirement: Must be administered in a healthcare setting with 30-minute post-injection observation due to risk of pulmonary oil microembolism (POME) and anaphylaxis. Available only through the Aveed REMS Program.

Topical Gels

Application instructions for gels:

• Apply to clean, dry, intact skin after showering
• Allow to dry completely (5–10 minutes) before dressing
• Do not apply to the genitals (except for Fortesta, which is specifically labeled for thigh application)
• Wash hands thoroughly after application
• Cover the application site with clothing after drying
• Avoid skin-to-skin contact with women and children for at least 2 hours (FDA boxed warning for secondary exposure virilization)

Transdermal Patches

• Starting dose: One Androderm 4 mg patch applied nightly
• Titration: Based on morning serum testosterone (drawn 3–12 hours after patch application)
• Dose range: 2–6 mg/day
• Site rotation: Apply to back, abdomen, upper arms, or thighs — rotate nightly to reduce skin irritation
• Note: Local reactions occur in up to 30% of patients; pretreatment with OTC triamcinolone 0.1% cream (applied to the skin, not the adhesive) may reduce irritation per the product label

Subcutaneous Pellets

• Starting dose: 150–450 mg (2–6 pellets of 75 mg each) implanted subdermally, typically in the hip/buttock area
• Redosing: Every 3–6 months based on symptom recurrence and trough testosterone levels
• Procedure: Performed under local anesthesia; incision ~5 mm; 5–10% pellet extrusion rate

Nasal Gel

• Dose: 11 mg testosterone per nostril, three times daily (total 66 mg/day), administered at least 6–8 hours apart
• Titration: Serum testosterone checked after 1 month (drawn 1–2 hours after a dose)

---

Monitoring: Required Labs and Schedule

Safe testosterone replacement therapy dosing depends on structured follow-up. Both the Endocrine Society and AUA recommend the following monitoring protocol:

Hematocrit is the most common safety concern during TRT. Testosterone stimulates erythropoiesis; hematocrit >54% warrants dose reduction, phlebotomy, or temporary discontinuation. The threshold for intervention is lower (>50%) in patients with existing cardiovascular disease or sleep apnea.

PSA: A rise of >1.4 ng/mL within any 12-month period or a total PSA >4.0 ng/mL should prompt urological referral. The Endocrine Society emphasizes that TRT does not cause prostate cancer, but it may stimulate growth of occult, pre-existing disease.

---

Side Effects and Safety

Common Adverse Effects

• Erythrocytosis (polycythemia): Most common — incidence approximately 5–20% depending on formulation and dose
• Acne and oily skin: More common with injectable formulations due to supraphysiological peaks
• Fluid retention/edema: Mild; usually self-limiting
• Gynecomastia: Due to aromatization of testosterone to estradiol; more common in obese men
• Testicular atrophy and infertility: Exogenous testosterone suppresses gonadotropins → reduced intratesticular testosterone → impaired spermatogenesis
• Sleep apnea: May worsen existing obstructive sleep apnea; monitor symptoms
• Skin reactions: Patches (~30%), gels (~5%)

Cardiovascular Safety: The TRAVERSE Trial

For years, the cardiovascular safety of TRT was uncertain. The 2010 TOM trial was stopped early due to excess cardiovascular events in older, frail men receiving testosterone gel, and two retrospective studies (Vigen et al., 2013; Finkle et al., 2014) raised further alarm — prompting the FDA to issue a 2015 safety communication requiring labeling changes.

The TRAVERSE trial (Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men; Lincoff et al., New England Journal of Medicine, 2023) was a landmark, FDA-mandated, randomized, double-blind, placebo-controlled trial in 5,246 men aged 45–80 with hypogonadism (testosterone <300 ng/dL) and pre-existing cardiovascular disease or high cardiovascular risk. Key findings:

• Primary endpoint (MACE — cardiovascular death, nonfatal MI, nonfatal stroke): Hazard ratio 0.99 (95% CI 0.81–1.21) — non-inferior to placebo. TRT did not increase MACE.
• Incidence of prostate cancer and high-grade prostate events: No significant difference between groups.
• Erythrocytosis and venous thromboembolism: Numerically higher with testosterone (but absolute risk remained low).
• Atrial fibrillation and acute kidney injury: Slightly higher incidence in the testosterone group — requires ongoing surveillance.

Clinical takeaway: The TRAVERSE trial provides reassurance that TRT at guideline-recommended doses does not increase the risk of major cardiovascular events in men with or at risk for cardiovascular disease. However, it does not establish cardiovascular benefit, and individualized risk assessment remains essential.

---

Contraindications and Drug Interactions

Absolute Contraindications

Relative Contraindications

• Benign prostatic hyperplasia (BPH) with severe lower urinary tract symptoms (IPSS >19)
• History of venous thromboembolism (assess risk-benefit)
• Erythrocytosis-prone conditions (chronic hypoxia, COPD)

Drug Interactions

• Anticoagulants (warfarin, heparin): Testosterone may enhance anticoagulant effect — monitor INR closely; dose reductions may be needed.
• Insulin and oral hypoglycemics: Testosterone may improve insulin sensitivity — monitor for hypoglycemia and adjust diabetes medications.
• Corticosteroids: Concurrent use increases edema risk.
• 5-alpha reductase inhibitors (finasteride, dutasteride): May reduce conversion to DHT; combined use requires awareness but is not contraindicated.

---

Special Populations

Older Men (>65 Years)

The Endocrine Society recommends against routine testosterone supplementation in older men with age-related testosterone decline unless they meet full diagnostic criteria (biochemical + symptomatic). The Testosterone Trials (TTrials, 2016) showed modest improvements in sexual function and walking distance but no significant effects on vitality or cognitive function in men ≥65.

Obese Men

Obesity is the most common reversible cause of low testosterone. Weight loss of 5–10% can increase testosterone levels by 50–100 ng/dL. The Endocrine Society recommends lifestyle intervention and weight management before or alongside TRT initiation.

Men Seeking Fertility

Standard TRT suppresses the HPG axis and causes oligospermia or azoospermia — often within 3–6 months. TRT should not be used as male contraception (suppression is unreliable), and it should be avoided in men desiring fertility. Alternatives include:

• Human chorionic gonadotropin (hCG): 1,500–5,000 IU subcutaneously 2–3 times weekly — maintains intratesticular testosterone and spermatogenesis
• Clomiphene citrate: 25–50 mg orally every other day or daily (off-label) — stimulates endogenous production via SERM activity
• Nasal testosterone (Natesto): Preliminary data suggest less HPG axis suppression, though long-term fertility data remain limited

Transgender Men (Female-to-Male)

Testosterone is the mainstay of masculinizing hormone therapy. The Endocrine Society guideline (2017) recommends testosterone cypionate or enanthate 50–100 mg IM weekly (or equivalent), titrated to male-range testosterone (320–1,000 ng/dL). Monitoring includes the same labs as cisgender men, plus screening for conditions related to natal anatomy.

---

Red Flags — When to Seek Immediate Medical Attention

Stop TRT and contact your prescriber or emergency services immediately if you experience:

• Sudden severe headache, chest pain, or shortness of breath — may indicate stroke, MI, or pulmonary embolism
• Leg swelling, warmth, or redness (unilateral) — signs of deep vein thrombosis
• Difficulty breathing or cough after an intramuscular injection (especially Aveed) — may indicate pulmonary oil microembolism
• Priapism (painful erection lasting >4 hours) — urological emergency
• Signs of allergic reaction — rash, facial swelling, difficulty breathing
• Jaundice or severe abdominal pain — rare hepatotoxicity (primarily associated with oral 17-alpha-alkylated androgens, which are not standard TRT)
• Mood disturbance: Severe aggression, mania, or suicidal ideation — dose-dependent, more common at supraphysiological doses

---

Frequently Asked Questions

1. How long does it take for TRT to work?

Effects emerge at different rates. Libido and energy improvements may appear within 3–6 weeks. Body composition changes (increased lean mass, decreased fat mass) typically require 3–6 months. Bone density improvements may take 12–24 months. Full effects on mood and cognitive function are generally seen by 3 months, though individual responses vary.

2. Is testosterone gel or injection better?

Neither is universally superior — the best formulation depends on patient preference, lifestyle, and clinical factors. Injections are less expensive and dosed weekly or biweekly, but produce peak-trough fluctuations. Gels provide more stable day-to-day levels but require daily application, carry transference risk, and are costlier. The AUA guideline states that all FDA-approved formulations are effective, and shared decision-making should guide selection.

3. Will TRT cause prostate cancer?

Current evidence does not support a causal link between TRT and prostate cancer development. The TRAVERSE trial showed no significant difference in prostate cancer incidence between testosterone and placebo groups. However, TRT is contraindicated in men with known metastatic prostate cancer, and PSA monitoring is required during treatment.

4. Can I stop TRT once I start?

Yes, but abrupt discontinuation may cause a period of symptomatic hypogonadism (fatigue, low mood, decreased libido) as the HPG axis recovers — which may take weeks to months, particularly after prolonged therapy. Gradual tapering and clinical monitoring are recommended.

5. Does TRT affect fertility?

Yes. Exogenous testosterone suppresses gonadotropins and can cause azoospermia. Spermatogenesis generally recovers within 6–12 months of discontinuation, though recovery is not guaranteed in all men. Men desiring fertility should discuss alternatives (hCG, clomiphene, or nasal testosterone) before starting standard TRT.

6. What happens if my hematocrit gets too high?

Hematocrit >54% increases the risk of thromboembolic events (stroke, DVT, PE). Management options include dose reduction, switching from injections to gels/patches (which cause less erythrocytosis), therapeutic phlebotomy, or temporary TRT discontinuation. Your prescriber should check hematocrit at every monitoring visit.

7. Is over-the-counter testosterone available?

No. Testosterone is a Schedule III controlled substance in the United States and requires a prescription. Products marketed as "testosterone boosters" (containing DHEA, tribulus, fenugreek, D-aspartic acid, etc.) are dietary supplements with no reliable evidence of meaningfully raising serum testosterone to therapeutic levels. They are not substitutes for TRT.

8. Can women receive testosterone therapy?

Testosterone therapy in women is considered off-label in most countries. The Global Position Statement (2019) from the International Menopause Society supports low-dose transdermal testosterone (approximately 5 mg/day) for hypoactive sexual desire disorder in postmenopausal women, with monitoring for androgenic side effects. Formulations are not specifically approved for women in the US.

---

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. PMID: 29562364

2. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423–432. PMID: 29601923

3. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107–117. PMID: 37334136

4. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611–624. PMID: 26886521

5. FDA. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging. 2015. FDA Safety Communication

6. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869–3903. PMID: 28945902

7. Corona G, Goulis DG, Huhtaniemi I, et al. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males. Andrology. 2020;8(5):970–987. PMID: 32026626

8. Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660–4666. PMID: 31498871

9. FDA. Label: Aveed (testosterone undecanoate) injection. 2014. Aveed Prescribing Information

10. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–1836. PMID: 24193080

---

About the Author

Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with over 15 years of experience in ambulatory care, endocrinology consultation, and medication therapy management. He writes for PillsCard.com with a focus on translating complex pharmacotherapy guidelines into practical, evidence-based content for patients and caregivers. His work emphasizes accuracy, transparency, and guideline concordance.

---

Medical Disclaimer

This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Testosterone is a prescription medication and controlled substance that must be prescribed and monitored by a qualified healthcare provider. Individual dosing decisions depend on clinical context that cannot be captured in a general reference article. Never start, stop, or change the dose of any medication without consulting your prescriber. If you are experiencing symptoms of low testosterone, schedule an appointment with your physician or endocrinologist for proper evaluation. In case of emergency, contact your local emergency services immediately.